Professor Miles Prince is a clinician-researcher haematologist whose work has made a major impact in patient care and our understanding of the mechanism of action of a variety of novel agents now used routinely in cancer therapy. His contribution within the field of translational research has been in the areas of myeloma exploring a variety of new agents, cell-based therapy particularly with respect to immune therapies for blood cancer, he is an international leader in the management of cutaneous lymphoma, and has led numerous trials that have led to the regulatory approval of new epigenetic-targeted therapies. In addition, he has made major contribution to patient care through involvement in health and science education, patient support groups and philanthropic leadership.